GW2580

GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling[1].

Product Specifications

CAS Number

[870483-87-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Fms

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/GW2580.html

Purity

99.90

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |Ethanol : < 1 mg/mL (ultrasonic)

Smiles

NC1=NC(N)=C(CC2=CC(OC)=C(OCC3=CC=C(OC)C=C3)C=C2)C=N1

Molecular Formula

C20H22N4O3

Molecular Weight

366.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Conway JG, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102 (44) :16078-83.|[2]Priceman SJ, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010 Feb 18;115 (7) :1461-71|[3]Conway JG, et al. Effects of the cFMS kinase inhibitor 5- (3-methoxy-4- ((4-methoxybenzyl) oxy) benzyl) pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 2008 Jul;326 (1) :41-50.